Overview

First in Human Study of M1069 in Advanced Solid Tumors

Status:
Not yet recruiting

Trial end date:
2023-12-14

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and early signs of efficacy of M1069 in participants with advanced solid malignancies.

Phase:

Phase 1

Details

Lead Sponsor:

EMD Serono Research & Development Institute, Inc.

Collaborator:

Merck KGaA, Darmstadt, Germany